Equities research analysts expect FibroGen Inc (NASDAQ:FGEN) to report sales of $45.37 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for FibroGen’s earnings, with the highest sales estimate coming in at $57.03 million and the lowest estimate coming in at $37.64 million. FibroGen posted sales of $31.91 million in the same quarter last year, which suggests a positive year-over-year growth rate of 42.2%. The business is expected to announce its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that FibroGen will report full year sales of $45.37 million for the current year, with estimates ranging from $120.80 million to $140.19 million. For the next financial year, analysts expect that the company will post sales of $229.55 million per share, with estimates ranging from $207.00 million to $248.35 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover FibroGen.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.13). FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%.

Several analysts have recently weighed in on the stock. ValuEngine upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Mizuho reaffirmed a “hold” rating and set a $61.00 target price on shares of FibroGen in a report on Thursday, November 9th. Four investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. FibroGen has a consensus rating of “Buy” and a consensus price target of $65.67.

FibroGen (NASDAQ:FGEN) traded down $1.75 during trading on Monday, hitting $52.20. 205,361 shares of the stock traded hands, compared to its average volume of 593,205. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. The stock has a market cap of $4,422.22, a PE ratio of -26.45 and a beta of 1.74. FibroGen has a 12-month low of $22.75 and a 12-month high of $63.00.

In related news, insider K Peony Yu sold 10,000 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $62.00, for a total transaction of $620,000.00. Following the transaction, the insider now owns 152,086 shares of the company’s stock, valued at approximately $9,429,332. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Thomas F. Kearns, Jr. sold 18,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $45.22, for a total transaction of $813,960.00. Following the transaction, the director now directly owns 156,564 shares in the company, valued at approximately $7,079,824.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 328,917 shares of company stock worth $16,142,651. 13.60% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP bought a new stake in FibroGen in the 2nd quarter worth $128,000. Bank of Montreal Can grew its holdings in FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 3,041 shares during the last quarter. Fortaleza Asset Management Inc. grew its holdings in FibroGen by 95.0% in the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 1,700 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in FibroGen by 41.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 1,147 shares during the last quarter. 57.11% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect FibroGen Inc (FGEN) Will Post Quarterly Sales of $45.37 Million” was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/02/08/zacks-brokerages-expect-fibrogen-inc-fgen-will-post-quarterly-sales-of-45-37-million.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.